دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies
Munazza Tamkeen Fatima MSc, PhD, Ikhlak Ahmed MSc, PhD, Khalid Adnan Fakhro MSc, PhD, Ammira Sarah Al-Shabeeb Akil MSc, EMBA, PhD
doi : 10.1111/dom.14618
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin
Fernando Gomez-Peralta MD, PhD, Pratik Choudhary MD, PhD, Emmanuel Cosson MD, PhD, Concetta Irace MD, PhD, Birgit Rami-Merhar MD, PhD, Alexander Seibold MD, PhD
doi : 10.1111/dom.14638
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial
Julie Dubourg MD, Pascale Fouqueray MD, Damien Quinslot MSc, Jean-Marie Grouin PhD, Kohei Kaku MD
doi : 10.1111/dom.14613
Body mass index and cancer mortality in patients with incident type 2 diabetes: A population-based study of adults in England
Nasra N. Alam MRCS, PhD, Alison K. Wright PhD, Martin K. Rutter MD, FRCP, Iain Buchan MD, FFPH, Darren M. Ashcroft PhD, FRPharmS, Matthew Sperrin PhD, Andrew G. Renehan FRCS, PhD
doi : 10.1111/dom.14614
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
Esteban Jódar PhD, Irene Romera PhD, Qianqian Wang PhD, Sarah Louise Roche PhD, Luis-Emilio GarcÃa-Pérez PhD
doi : 10.1111/dom.14615
Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population-based analysis from 2010 to 2020
Kristin K. Clemens MD, Alexandra M. Ouédraogo MSc, Melody Lam MSc, Flory Tsobo Muanda PhD, Emma Loeschnik BSc, Piotr Wilk PhD, Salimah Z. Shariff PhD
doi : 10.1111/dom.14622
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
Odette S. Reifsnider PhD, Pratik Pimple PhD, Sarah Brand MSc, Evelien Bergrath Washington MSc, Sharash Shetty PhD, Nihar R. Desai MD
doi : 10.1111/dom.14625
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
Kohei Kaku MD, Christoph Wanner MD, Stefan D. Anker MD, Stuart Pocock PhD, Atsutaka Yasui PhD, Michaela Mattheus Dipl Biomath, Søren S. Lund MD
doi : 10.1111/dom.14626
Where can you wear your Libre? Using the FreeStyle Libre continuous glucose monitor on alternative sites
Rosemary M. Hall Phd, Sophie Dyhrberg MBChB, Arthur McTavish, Lindsay McTavish, Brian Corley PhD, Jeremy D. Krebs MD
doi : 10.1111/dom.14630
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Juris J. Meier MD, Charlotte Granhall PhD, Ulrike Hoevelmann MD, Andrea Navarria MD, Leona Plum-Moerschel MD, Chethana Ramesh MSc, Andrea Tannapfel MD, Christoph Kapitza MD
doi : 10.1111/dom.14632
Effects of a 6-month, low-carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open-label randomized controlled trial
Eva M. Gram-Kampmann MD, Camilla D. Hansen MD, Mie B. Hugger MD, Jane M. Jensen MSc, Jan C. Brønd MSc, Anne Pernille Hermann PhD, Aleksander Krag PhD, Michael H. Olsen PhD, Henning Beck-Nielsen DMSc, Kurt Højlund PhD
doi : 10.1111/dom.14633
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
Peter J. Raubenheimer MBBCh, William C. Cushman MD, Alvaro Avezum MD, Jan Basile MD, Ignacio Conget MD, Gilles Dagenais MD, Anastasia Hoover PharmD, Petr Jansky MD, Fernando Lanas MD, Lawrence A. Leiter MD, Patricio Lopez-Jaramillo MD, Nana Pogosova MD, Jeffrey Probstfield MD, Purnima Rao-Melacini MSc, Lars Rydén MD, Wayne H.-H. Sheu MD, Theodora Temelkova-Kurktschiev MD, Hertzel C. Gerstein MD
doi : 10.1111/dom.14634
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study
Leona Plum-Mörschel MD, PhD, Gursharan Singh MBBS, PhD, Sundara Moorthi Nainar Murugesan MPharm, PhD, Ashwani Marwah MSc, Jayanti Panda MPharm, Subramanian Loganathan MD, Sandeep N. Athalye MD
doi : 10.1111/dom.14635
Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis
Ke He MS, Qing Guo PhD, Haijuan Zhang MS, Wang Xi MS, Jingxin Li MS, Zeng Jing BS
doi : 10.1111/dom.14612
Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database
Svenja Meyhöfer MD, Alexander J. Eckert, Michael Hummel MD, Markus Laimer MD, Michael Roden MD, Stephan Kress MD, Jochen Seufert MD, Sebastian M. Meyhöfer MD, Reinhard W. Holl MD
doi : 10.1111/dom.14616
The relationship between hypoglycaemia and glucose variability in type 1 diabetes
Jordan E. Perlman MD, Theodore A. Gooley PhD, Jedidiah Meyers DO, Irl B. Hirsch MD
doi : 10.1111/dom.14617
Self-reported regular daytime napping is associated with indicators of poor type 2 diabetes control: A cohort study
Pei Xue MD, Xiangdong Tang MD, Xiao Tan PhD, Christian Benedict PhD
doi : 10.1111/dom.14619
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis
Jochen Seufert MD, FRCPE, Stefanie Lanzinger PhD, MSc, Thomas Danne MD, Peter Bramlage MD, Sebastian M. Schmid MD, Florian Kopp MD, Stephan Kress MD, Peter Fasching MD, Claus Schäfer MD, Reinhard W. Holl MD, the DPV Initiative
doi : 10.1111/dom.14620
Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide
Timothy L. Middleton MPhil, Maria I. Constantino PhD, Margaret McGill MSc, Mario D’Souza PhD, Dennis K. Yue PhD, Stephen M. Twigg PhD, Ted Wu PhD, Jencia Wong PhD
doi : 10.1111/dom.14621
Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial
Eugene Han MD, Ji Hye Huh MD, Eun Y. Lee MD, Ji C. Bae MD, Sung W. Chun MD, Sung H. Yu MD, Soo H. Kwak MD, Kyong S. Park MD, Byung-Wan Lee MD
doi : 10.1111/dom.14623
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects
Soo Lim MD, Minji Sohn PhD, Yujin Shin MD, Ele Ferrannini MD
doi : 10.1111/dom.14627
Metabolically healthy obesity and cardiovascular events: A risk of obesity
Tomoyuki Kawada MD
doi : 10.1111/dom.14628
Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?
Leszek Czupryniak MD, Thomas Danne MD, Elektra Szymańska-Garbacz MD, Dorota Zozulińska-Ziółkiewicz MD, Janusz Gumprecht MD, Tomasz Klupa MD
doi : 10.1111/dom.14631
